Cure JM Funded & Partner Clinical Trials

Cure JM is dedicated to funding and collaborating on the most promising juvenile myositis research clinical trials to shape a future free of JM. We are dedicated to supporting better treatment options through the clinical trial process to improve the lives of generations of JM patients.

CAR-T Myositis Clinical Trial

We are supporting clinical trials for promising innovative new treatments like CAR-T, a potential “immune system reset” for juvenile myositis. Early data shows promise for this therapy in cancer and autoimmune diseases like JM.

Cure JM partner Cabaletta Bio has recently opened up an adult CAR-T myositis trial for myositis patients over 18 years old, with an expected adolescent trial in the coming month, so check back regularly for updates. Learn more about this clinical trial and Cabaletta Bio’s early promising results at https://www.curejm.org/car-ttherapypotential/

JAK Inhibitor Clinical Trial – Deucravacitinib

In 2017, we partnered on a project with the NIH to screen thousands of U.S.-registered drugs to uncover compounds and drugs that are the strongest candidates for best treating juvenile myositis with fewer side effects.

Dr. Travis Kinder and the drug discovery team the NIH team.

The outcome of this screening identified several JAK inhibitors, with a drug named deucravacitinib (Sotyktu), a promising candidate to be safe and effective in treating JM, with the hope of reducing reliance on steroids and chemo treatments. Deucravacitinib shows promise in JM with a low side effect profile.

Cure JM’s research partners at the NIH will open enrollment by early 2025. The trial will begin with patients aged 18 and older, and we expect adolescents to be added to it in 2025.

Vamorolone – A Potential Steroid Alternative

We are funding pre-trial work on vamorolone with key researchers at Cure JM’s Center of Excellence at Duke University to advance a clinical trial plan with the FDA. Vamorolone is a new steroid alternative that was recently approved by the FDA for treating Duchenne Muscular Dystrophy. Vamorolone shows promise in providing the powerful benefits of corticosteroids without the harsh side effects that are often associated with prednisone.

Cure JM is working closely with Duke University, the FDA, and the distributors of vamorolone on a clinical trial plan to test safety and efficacy of the drug in JM.

2022 Cure JM Medical Symposium

Juvenile Dermatomyositis: Advances in Basic Research, Translational Studies and Clinical care. Hosted by Duke University and Cure JM Foundation. March 12th, 2022.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.